ARCH II Study (Alcohol Research Center on HIV Study II)

Alcohol and HIV: Biobehavioral Interactions and Intervention

This study is being done to learn about the interaction of alcohol consumption and HIV on brain function. The proposed study will have two broad objectives. The first is to incorporate functional neuroimaging (FMRI) approaches, along with additional Magnetic Resonance Spectroscopy (MRS) methods that will enable a delineation in both functional and cerebral metabolic disturbances affecting specific functional brain systems that are associated with the interaction of ethanol (ETOH) consumption on Human Immunodeficiency Virus (HIV)-associated brain dysfunction. Recent data indicate that HIV infected patients with heavy ETOH consumption have FMRI abnormalities and exhibit alterations on other neuroimaging measures compared to moderate drinkers and people who do not drink at all. The second objective is to examine the extent to which reductions in ETOH consumption among heavy drinkers with HIV infection result from a motivational intervention. The findings from this study will provide important information on how heavy ETOH and HIV interact to affect the brain functional responsiveness, and the extent of improvement that might be gained by reducing heavy ETOH use.

Study Overview

• Status: Completed
• Conditions: HIV; Alcohol Consumption; Motivation
• Intervention / Treatment: Behavioral: Motivational Interviewing; Other: Questionnaire assessment; Other: Neurocognitive assessments; Other: Blood specimens

Detailed Description

In this research study, participants will be randomized (much like flipping a coin) by a computer program to either no counseling or FMRI during the baseline visit in the second session for this visit.

Each time point (baseline, 3 months and 9 months) consists of 2 participant sessions. Session 1) at baseline is for the purposes of recruiting and determining if participants meet study criteria; during all visits, study criteria are reviewed to ensure that enrolled participants are still eligible. After determining eligibility, study information is explained by the research assistant and consent is then obtained. Additional psychiatric and substance use assessment and neurological and will be performed. Blood and urine specimens will be obtained and sent to lab for measurement of immunological, virologic, and hepatic status and other biomarkers. The remainder of the blood specimens will be frozen and banked for future analyses. All blood specimens banks for future analyses will be deidentified. A neurocognitive assessment performed by a research assistant. The duration will be approximately 120 minutes. Session 2) will occur within one week of visit one. It will consist of an MRI scan lasting approximately 50 minutes. Functional imaging will be conducted during this MRI time. All participants will undergo all procedures at baseline, and three and nine months.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32610
      • University of Florida
    • Miami, Florida, United States, 33199
      • Florida International University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• HIV-infected;
• English speaking;
• Physically mobile;
• Willingness to participate in the Motivational Interviewing (MI) to reduce ETOH consumption.

Exclusion Criteria:

• Neurological disorders;
• Evidence of dementia;
• Past opportunistic brain infection;
• Major psychiatric illness;
• Current major psychiatric disturbance;
• Unstable medical conditions (cancer);
• MRI contraindications (e.g., pregnancy, claustrophobia, metal implants);
• Physical impairment precluding motor response or lying still.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Motivational Interviewing Group; This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.	Behavioral: Motivational Interviewing; A type of counseling aimed at reducing consumption of alcohol.; Other: Questionnaire assessment; Several different types of questionnaires will be fill out by the participants.; Other: Neurocognitive assessments; Several different types of neurocognitive assessment will be performed.; Other: Blood specimens; Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
Active Comparator: Control Group; This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.	Other: Questionnaire assessment; Several different types of questionnaires will be fill out by the participants.; Other: Neurocognitive assessments; Several different types of neurocognitive assessment will be performed.; Other: Blood specimens; Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FMRI images will be performed for changes in the brain between the groups	Cerebral metabolite abnormalities	Baseline and 6 month follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-IV (SCID)	A structured interview given to participants in order to assess current and past alcohol use and dependence	Baseline
Lifetime Alcohol and Drug Use History	This interview will be conducted at baseline to gather information about age of onset of alcohol use, period of heaviest drinking, most drinks consumed on a single day, and number of drug classes used lifetime.	Baseline
Kreek-McHugh-Schluger-Kellogg (KMSK) Scale	Developed as a research measure of drug use severity in accordance with DSM-IV criteria, the KMSK is reliable and valid, quantifying frequency, duration, and amount of individual drug use.	Baseline, 3-month, 6-month, and 12-month follow-ups.
Timeline Followback (TLFB)	The TLFB interview will be used to assess recent alcohol use at baseline, as well as during the follow-up intervals. The TLFB interview is a calendar-assisted structured interview which provides a way to cue memory so that accurate recall is enhanced. The TLFB will provide data on the percentage of drinking days, drinks consumed per week, and the percentage of heavy drinking days.	Baseline, 3-month, 6-month, and 12-month follow-ups.
Urine Drug Screen	Urine drug screens will be performed using Varian's TestCup Pro5, testing for benzodiazepines, amphetamines, opiates, & cocaine.	Baseline, 3-month, 6-month, and 12-month follow-ups.
Short Inventory of Problems (SIP)	The SIP assesses 15 negative consequences of alcohol use over the chosen time period (in this case 3 months) and has been found to have good psychometric properties. Maximum score is 45	Baseline, 3-month, 6-month, and 12-month follow-ups.
Epworth Sleepiness Scale (ESS)	The ESS proposes eight daytime scenarios, and the participant is asked to rate how likely they are to fall asleep in each situation on a four-point scale (0-3).	Baseline, 3-month, 6-month, and 12-month follow-ups.
Center for Epidemiological Studies-Depression Scale (CES-D)	A 20-item screening test for depression and depressive disorder	Baseline, 3-month, 6-month, and 12-month follow-ups.
Beck Anxiety Inventory	21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety	Baseline, 3-month, 6-month, and 12-month follow-ups.
Early Life Stress Questionnaire (ELSQ)	A 5-section self-report questionnaire assessment of adverse childhood events	Baseline
The Frontal System Behavioral Scale (FrSBe)	A 46-item self-report questionnaire designed to measure behavior related to frontal systems damage	Baseline, 3-month, 6-month, and 12-month follow-ups.
Medical Outcomes Study HIV Health Survey (MOS-HIV)	A 35-item self-report questionnaire designed in order to assess functional status and well-being among HIV-positive individuals	Baseline, 3-month, 6-month, and 12-month follow-ups.
Montreal Cognitive Assessment (MoCA)	measurement used to screen for dementia and mild cognitive impairment	Baseline, 3-month, 6-month, and 12-month follow-ups.
Hopkins Verelan Learning Test Revised (HVLT-R)	cognitive assessment that measures verbal learning and memory	Baseline, 3-month, 6-month, and 12-month follow-ups.
Brief Visuospatial Memory Test Revised (BVMT-R)	A measure of visuospatial memory	Baseline, 3-month, 6-month, and 12-month follow-ups.
Paced Auditory Serial Addition Test (PASAT-1)	A cognitive assessment which measures visuospatial memory	Baseline, 3-month, 6-month, and 12-month follow-ups.
WAIS-3 Letter Number Sequencing	7-item cognitive assessment with a total of 21 maximum points	Baseline, 3-month, 6-month, and 12-month follow-ups.
WAIS-3 Digit Symbol	A timed neuropsychological test sensitive to brain damage, dementia, age and depression consisting of digit-symbol pairs followed by a list of digits	Baseline, 3-month, 6-month, and 12-month follow-ups.
WAIS-3 Symbol Search	Cognitive assessment measuring processing speed with a total max score of	Baseline, 3-month, 6-month, and 12-month follow-ups.
Trail Making	timed cognitive assessment looking at working memory and executive functioning	Baseline, 3-month, 6-month, and 12-month follow-ups.
Grooved Pegboard	measures performance speed in a fine motor task	Baseline, 3-month, 6-month, and 12-month follow-ups.
Stroop Task	timed cognitive task	Baseline, 3-month, 6-month, and 12-month follow-ups.
Verbal Fluency	timed language measure	Baseline, 3-month, 6-month, and 12-month follow-ups.
Animal Fluency	timed language measure	Baseline, 3-month, 6-month, and 12-month follow-ups.
The Wechsler Test of Adult Reading (WTAR)	cognitive tast measuring verbal intelligence	Baseline, 3-month, 6-month, and 12-month follow-ups.
Boston Naming Test		Baseline, 3-month, 6-month, and 12-month follow-ups.
Adaptive Rate Continuous Performance Test (ARCPT)	computerized adaptive task measuring attention	Baseline, 3-month, 6-month, and 12-month follow-ups.
California Computerized Assessment Package (CalCAP)	computerized task measuring reaction time	Baseline, 3-month, 6-month, and 12-month follow-ups.

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA); Brown University
• Investigators: Principal Investigator: Ron Cohen, Ph.D, University of Florida

Study record dates

Study Major Dates

• Study Start: December 1, 2016
• Primary Completion (Actual): December 16, 2021
• Study Completion (Actual): December 16, 2021

Study Registration Dates

• First Submitted: September 28, 2015
• First Submitted That Met QC Criteria: September 28, 2015
• First Posted (Estimate): September 30, 2015

Study Record Updates

• Last Update Posted (Actual): April 4, 2022
• Last Update Submitted That Met QC Criteria: March 23, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Motivational Interviewing; Alcohol and brain function; HIV and brain function
• Additional Relevant MeSH Terms: Drinking Behavior; Alcohol Drinking
• Other Study ID Numbers: IRB201500625-N; 2P01AA019072-06 (U.S. NIH Grant/Contract); OCR16162 (Other Identifier: Universiy of Florida)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No